Top Markets
#1 Black Phoenix Black Phoenix +355.27%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.66%
#4 OpenEden OpenEden +56.84%
#5 Akedo Akedo +56.63%
#6 BasedHype BasedHype +27.37%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +20.66%
#9 Humanity Humanity +17.61%
#10 Ether.fi Ether.fi +17.54%
Coin of the day
Black Phoenix Black Phoenix
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rang în acțiuni #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Preț acțiune
$0.01292666
Ultima sincronizare: 2025-04-08
Capitalizare de piață
$157.54K
Schimbare (1 zi)
6.84%
Schimbare (1 an)
0.00%
Țară
GB
Tranzacționează Synairgen plc (SNG)

Categorie

Healthcare
Venituri pentru Synairgen plc (SNG)
Venituri în Jun 2024 TTM: 0.00
Conform celor mai recente rapoarte financiare ale Synairgen plc, venitul actual al companiei (TTM) este 0.00. În anul 2022, compania a avut un venit de 0.00 egal cu venitul din anul 2021, care a fost de 0.00. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Synairgen plc din 2004 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $133.74 -98.03%
2017 $6.79K 0.00%
2016 0.00 -100.00%
2015 $36.84 -99.45%
2014 $6.68K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 $248.65K 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 $156.44K 3.46%
2006 $151.21K -58.23%
2005 $361.99K 143.32%
2004 $148.77K 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE